# Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

> **NCT05866432** · PHASE2 · RECRUITING · sponsor: **Medical University of Vienna** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Datopotamab deruxtecan

## Key facts

- **NCT ID:** NCT05866432
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-05-23
- **Final completion:** 2026-05-23
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866432, "Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05866432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*